Predicting cognitive decline in Alzheimer's disease

Takeaway

  • Positron emission tomography (PET) biomarkers are stronger predictors of cognitive decline in Alzheimer’s disease (AD) than MRI measures of atrophy and demographic data.

Why this matters

  • This analysis simultaneously compared tau pathology, neuroinflammation and brain atrophy in patients with amyloid-positive mild cognitive impairment (MCI) and Alzheimer's dementia.

  • Increasing our understanding of how baseline measures of these three biomarkers predict cognitive decline across the whole spectrum of AD is critically important for two reasons. Firstly, it could provide a step forward in developing new prognostic markers of disease, and secondly, it could help develop effective tests that can ascertain the efficacy of new disease modifying therapies.